← Human Trials & Peer-Reviewed Studies
Impact of specialized oral nutritional supplement on clinical, nutritional, and functional outcomes: A randomized, placebo-controlled trial in community-dwelling older adults at risk of malnutrition.
Plain-language guide to PMID 33268143 (2021): randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 33268143
- Journal
- Clinical nutrition (Edinburgh, Scotland)
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Chew STH et al. (14 authors)
- DOI
- 10.1016/j.clnu.2020.10.015
- Registered trial
- NCT03245047
What This Study Did, in Plain Language
What Was Tested
Researchers studied Copper (Supplement) in this randomized controlled trial publication.
The world's over-65 population is expanding rapidly, and the risk of malnutrition is prevalent in this population.
The objective of this randomized, controlled trial was to determine the effects of oral nutritional supplement (ONS) containing beta-hydroxy-beta-methylbutyrate (HMB), along with dietary counseling, on health outcomes in community-dwelling older adults at risk of malnutrition.
Who Took Part
PubMed indexes the participants as older adults, both men and women.
Participants were community ambulant and classified as medium or high risk for malnutrition using Malnutrition Universal Screening Tool (MUST).
How the Study Was Run
The design is described as randomized and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
Dietary intakes, nutritional and functional outcomes were measured at baseline, 30, 90, and 180 days.
What Was Measured
PubMed files the paper under topics including Dietary Supplements, Geriatric Assessment, Hand Strength, Independent Living, Malnutrition, Nutritional Status and Risk.
Author keywords: Beta-hydroxy-beta-methylbutyrate (HMB), Community, Functional outcome, Older adults and Oral nutritional supplement.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Copper (Supplement).
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2021 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.